REGULATORY
CSIMC Recommends Listing of 9 Products Including Imusera; Recommendation Put on Hold for Ilaris
The Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended the listing of eight active pharmaceutical ingredients (APIs)/nine products including Imusera Capsule/Gilenya Capsule (fingolimod HCl; Mitsubishi Tanabe Pharma Corporation (MTPC)/Novartis Pharma), Japan’s first oral treatment for multiple sclerosis (MS), at a…
To read the full story
REGULATORY
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
- LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





